论文部分内容阅读
目的提高对乳腺癌骨转移患者预后影响因素的进一步认识,指导临床个体化治疗。方法回顾分析有完整病例资料的乳腺癌骨转移患者68例。结果68例患者的中位生存期20个月,乳腺癌骨转移合并肝脏和/或肺转移同时存在时,患者的中位生存期13.5个月;乳腺癌骨转移不合并肝脏和/或肺转移患者的中位生存期为26个月;仅有骨转移而不合并其他脏器转移的患者的平均生存时间为44.2个月。结论乳腺癌转移患者中肝脏和/或肺转移是预后不良指标。骨转移而不合并其他转移的患者生存期较长,其次是骨转移合并肺转移者、合并淋巴结转移、骨转移合并多个脏器转移者及合并肝脏转移者。
Objective To improve the prognosis of breast cancer patients with bone metastases to further understand the factors that guide the clinical individualized treatment. Methods A retrospective analysis of 68 cases of breast cancer patients with complete bone metastases. Results The median survival of 68 patients was 20 months. The median survival of patients with breast cancer with bone metastases combined with liver and / or lung metastases was 13.5 months. Bone metastases from breast cancer did not correlate with liver and / or lung metastases The median survival of patients was 26 months; the mean survival time of patients who had only bone metastases but not other organ metastases was 44.2 months. Conclusions Liver and / or lung metastases in patients with metastatic breast cancer are poor prognostic indicators. Patients with bone metastases without other metastases had a longer survival period, followed by patients with metastases of bone and lung, patients with metastasis of lymph nodes, multiple metastasis of bone metastases and patients with metastasis of liver.